A practical, two-day workshop that decodes the full ADC development journey — from CMC and analytical control through non-clinical, clinical and expedited pathways to global submissions and market ...
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary ...
WuXi XDC, a CRDMO, agreed to collaborate with Earendil Labs on WuXi XDC’s WuXiTecan-2 payload-linker technology platform. The partnership is aimed at accelerating the development of next-gen ADCs by ...
Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC ...
Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless ...
Mycenax Biotech Inc., a leading biologics CDMO based in Taiwan, announced strategic alliance with Spera Pharma Inc., a Japan-based expert in pharmaceutical chemistry, manufacturing, and controls (CMC) ...
SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- WuXi XDC ("XDC"), a leading global CRDMO company dedicated to end-to-end bioconjugates services, announced that it received the Runner Up prize in the "Best ...
TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...
TAIPEI, Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results